Diagnosis and Treatment of Endometriosis
Am Fam Physician. 1999 Oct 15;60(6):1753-1762.
See related patient information handout on endometriosis, written by the author of this article.
Endometriosis is a progressive disease affecting 5 to 10 percent of women. It can cause dyspareunia, dysmenorrhea, low back pain and infertility. A definitive diagnosis can be made only by means of laparoscopy. Medical treatment designed to interfere with ovulation generally provides effective pain relief, but the recurrence rate following cessation of therapy is high, and this type of treatment will not resolve infertility. Surgical treatment improves pregnancy rates and is the preferred initial treatment for infertility caused by endometriosis. Surgery also appears to provide better long-term pain relief than medical treatment. Bilateral oophorectomy and hysterectomy are treatment options for patients with intractable pain, if childbearing is no longer desired.
Endometriosis is characterized by the presence of endometrial tissue on the ovaries, fallopian tubes or other abnormal sites, causing pain or infertility. The disease tends to progress under the repetitive influence of the menstrual cycle. Interrupting or decreasing menstruation is the mainstay of medical therapy. The goal of surgery is to remove endometrial lesions. Endometriosis is likely to remain problematic as long as menstruation persists. Fortunately, symptoms can be modulated or alleviated with appropriate treatment.
Women are usually 25 to 29 years old at the time of diagnosis, which is frequently delayed in those who present with infertility rather than pain.1 A familial tendency has been identified.2 Endometriosis has been found in 4.1 percent of asymptomatic women undergoing laparoscopy for sterilization; however, evidence of the disease is present in 20 percent (range: 2 to 78 percent) of women undergoing laparoscopic investigation for infertility. Approximately 24 percent (range: 4 to 82 percent) of women who complain of pelvic pain are subsequently found to have endometriosis.3 The overall prevalence, including symptomatic and asymptomatic women, is estimated to be 5 to 10 percent.4 Because surgical confirmation is necessary for the diagnosis, the true prevalence of the disease is unknown.
Endometriosis is not well understood and is probably multifactorial in origin. The most widely embraced theory involves retrograde menstruation5 (Figure 1). Although reflux of menstrual fluid occurs in many, if not all, women, in endometriosis the refluxed cells implant in the pelvis, bleed in response to cyclic hormonal stimulation and increase in size along with progression of symptoms.6 Immune alterations may also contribute to the persistence of implants or endometriosis-associated infertility.7,8
Two other theories have received support. One holds that peritoneal epithelium can be “transformed” into endometrial tissue, perhaps because of chronic inflammation or chemical irritation from refluxed menstrual blood. This theory of “coelomic metaplasia” is based on the observation that coelomic epithelium is the common ancestor of endometrial and peritoneal cells, thus allowing transformation of one type of cell into another. A final theory hypothesizes that müllerian remnants can differentiate into endometrial tissue. The circumstances in which this would occur are not clear but, once endometrium is present, it will cause symptoms in a cyclic fashion.
Although retrograde menstruation seems almost certain to be involved in the pathogenesis of endometriosis, that theory does not explain the full spectrum of the disease. For example, endometrial implants are occasionally found in such remote sites as the lung or even the nose. Moreover, endometriosis also occurs, albeit rarely, in men taking large doses of estrogen. The theories of coelomic metaplasia and müllerian remnant differentiation are better suited than the theory of retrograde menstruation to explain some of these exceptional circumstances.
Clinical Features and Diagnostic Evaluation
Endometriosis should be considered in any woman of reproductive age who has pelvic pain (Table 1). The most common symptoms are dysmenorrhea, dyspareunia and low back pain that worsens during menses.9 Depending on the location of the implants, rectal pain and painful defecation may also occur. The diagnosis of endometriosis should be considered especially if a patient develops dysmenorrhea after years of pain-free menstrual cycles. Of course, other causes of secondary dysmenorrhea and chronic pelvic pain (e.g., upper genital tract infections, adenomyosis, adhesions) may produce similar symptoms.
TABLE 1 Differential Diagnosis of Endometriosis by Symptom
Differential Diagnosis of Endometriosis by Symptom
Generalized pelvic pain
Pelvic inflammatory disease
Neoplasms, benign or malignant
Sexual or physical abuse
Secondary (adenomyosis, myomas, infection, cervical stenosis)
Musculoskeletal causes (pelvic relaxation, levator spasm)
Gastrointestinal tract (constipation, irritable bowel syndrome)
Urinary tract (urethral syndrome, interstitial cystitis)
Pelvic vascular congestion
Diminished lubrication or vaginal expansion because of insufficient arousal
Tubal disease (infection)
Cervical factors (mucus, sperm antibodies, stenosis)
Luteal phase deficiency
Adapted with permission from Ryder RM. Chronic pelvic pain. Am Fam Physician 1996;54:2225.
Infertility may also be the presenting complaint. Infertile patients often have no painful symptoms, and their disease is only uncovered in the course of the diagnostic work-up for infertility. The reason for this divergence in clinical manifestations is unknown.
Physical examination should be performed during early menses, when implants are likely to be largest and most tender. The physician should palpate for a fixed, retroverted uterus, adnexal and uterine tenderness, pelvic masses or nodularity along the uterosacral ligaments. A rectovaginal examination is required to identify uterosacral, cul-de-sac or septal nodules. However, most women with endometriosis have normal pelvic findings, and laparoscopy is necessary for definitive diagnosis. Although no single laboratory test has shown reliable clinical utility, it is possible that eventually a combination of biochemical markers and clinical assessment will decrease the need for surgical confirmation.10,11
Pelvic ultrasonography, computed tomography and magnetic resonance imaging are occasionally used to identify individual lesions, but these modalities are not helpful in assessing the extent of endometriosis.12 Even with direct visualization, diagnosis of endometriosis can be difficult. Lesions appear in multiple guises that are at times difficult to interpret. This diagnostic challenge is compounded by the unreliable correlation between clinical manifestations and surgical findings.13 A patient who is asymptomatic or has very mild symptoms may have extensive disease, whereas an infertile patient may have very few implants. A better correlation between clinical and surgical disease may be observed in more severe cases: in at least one study14 it has been found that women with severe, chronic pelvic pain have a more advanced stage of disease at initial diagnosis.
The American Fertility Society's revised staging instrument can help standardize findings and document the patient's baseline condition and subsequent progress.15 Staging is based on location, diameter and depth of lesions, and density of adhesions. Stages range from minimal to severe disease. Despite this standardization, the correlation between stage and extent of disease remains controversial.
In most patients, confirmatory laparoscopy is required before treatment is instituted.4 In women with few symptoms, an empiric trial of oral contraceptives or progestins may be warranted to assess pain relief. Recently, an empiric three-month trial of therapy with gonadotropin-releasing hormone (GnRH) analogs has been a popular strategy.16 In severe or unresponsive cases, or in the investigation of infertility, exact diagnosis is required to direct management and to justify possibly unpleasant medical treatments. Patients with infertility should undergo a thorough basic evaluation for other causes of infertility before diagnostic laparoscopy is undertaken.
Treatment may be expectant, or a patient may choose either medical or surgical options. Infertile patients may increase the likelihood of subsequent conception by undergoing surgery, but medical treatment has not been shown to help these patients conceive.17,18 Furthermore, pregnancy is contraindicated in patients receiving medical treatment and is in fact unlikely, because the drugs that are used interfere with ovulation. Medical and surgical approaches have been successful in reducing the pain associated with endometriosis.
Medical treatment should be reserved for use in patients with pain or dyspareunia, because no pharmacologic method appears to restore fertility.
Danazol. Danazol (Danocrine) has been highly effective in relieving the symptoms of endometriosis, but adverse effects may preclude its use. (There are now other treatments that may be better tolerated.) Danazol is a synthetic androgen that inhibits leuteinizing hormone (LH) and follicle-stimulating hormone (FSH), resulting in a relatively hypoestrogenic state. Endometrial atrophy is the likely mechanism in the relief of pain from endometriosis. Adverse effects related to estrogen defiency include headache, flushing, sweating and atrophic vaginitis. Androgenic side effects include acne, edema, hirsutism, deepening of the voice and weight gain.
Danazol therapy should be started when the patient is menstruating. The initial dosage should be 800 mg per day, given in two divided oral doses, but this dosage can be titrated down as long as amenorrhea persists and pain symptoms are controlled. Patients with less severe symptoms may be given 200 to 400 mg per day, in two divided oral doses. Treatment duration is six months but can be extended to nine months in responsive patients with severe disease. The overall response rate is 84 to 92 percent, with beneficial effects lasting up to six months after treatment has stopped.12
GnRH Agonists. These agents (e.g., leuprolide [Lupron], gosarelin [Zoladex]) inhibit the secretion of gonadotropin and are comparable to danazol in relieving pain.12–19 Like danazol, GnRH agonists are contraindicated in pregnancy and have hypoestrogenic side effects. In particular, they have been shown to produce a mild degree of bone loss, although this condition reverses after the medication is discontinued. Because of concerns about osteopenia, “add-back” therapy with low-dose estrogen has been recommended but is not currently an FDA-labeled indication for estrogen replacement therapy.20,21
The dosage of leuprolide is a single monthly 3.75-mg depot injection given intramuscularly. Gosarelin, in a dosage of 3.6 mg, is administered subcutaneously every 28 days. A nasal spray (nafarelin [Synarel]) is also available and is used twice daily. The response rate is similar to that with danazol; about 90 percent of patients experience pain relief. The pregnancy rate after the use of these agents is no different from that in untreated patients.
Oral Contraceptive Pills. Oral contraceptive pills (OCPs) suppress LH and FSH and prevent ovulation. They also have direct effects on endometrial tissue, rendering it thin and compact. The decidualization of endometrial implants, coupled with reduced reflux related to lower menstrual volume, is the probable mechanism of pain relief with OCPs, making them comparable to other treatments in effect.9 Combination OCPs alleviate symptoms in about three quarters of patients. No hormonal combination appears to be more effective than another. They can be taken continuously (with no placebos) or cyclically, with a week of placebo pills between cycles. The OCPs can be discontinued after six to 12 months or continued indefinitely, depending on such factors as patient satisfaction and the desirability of pregnancy.
Progestational Agents. Progestins are similar to combination OCPs in their effects on FSH, LH and endometrial tissue. They may be associated with more bothersome adverse effects than OCPs and, if a depot form (i.e., medroxyprogesterone suspension [Depo-Provera]) is used, return to fertility may be delayed. Nonetheless, progestins are effective in reducing the symptoms of endometriosis. One study that pooled data from 14 investigations found no significant difference between the efficacy of progestins and that of any other medical treatment.22 Although this conclusion was based on analysis of the combined results of a handful of small, heterogeneous studies, it is important because progestins are much cheaper than either danazol or GnRH analogs.
Given the likelihood of comparable efficacy, as well as the certainty of a high rate of recurrence regardless of the agent used, physicians may elect to prescribe OCPs or progestins as first-line agents on the basis of cost alone. If effective, these agents can be used safely for long periods of time. Progestins can be given orally on a daily basis or delivered by injection. Oral regimens may include once-daily administration of medroxyprogesterone at the lowest effective dosage (5 to 20 mg). Depot medroxyprogesterone has been given intramuscularly every two weeks for two months at 100 mg per dose and then once a month for four months at 200 mg per dose. Medical treatments are reviewed in Table 2.
TABLE 2 Medical Treatment of Endometriosis
Medical Treatment of Endometriosis
800 mg per day in 2 divided doses
Estrogen deficiency, androgenic side effects
$410, brand 367, generic
1 pill per day (continuous or cyclic)
Headache, nausea, hypertension
29 brand† 24 to 27‡, generic
Medroxyprogesterone suspension (Depo-Provera)
100 mg IM every 2 weeks for 2 months; then 200 mg IM every month for 4 months or 150 mg IM every 3 months
Weight gain, depression, irregular menses or amenorrhea
22, brand 13, generic
5 to 20 mg orally per day
Same as with other oral progestins
Norethindrone acetate (Aygestin)
5 mg per day orally for 2 weeks; then increase by 2.5 mg per day every 2 weeks up to 15 mg per day
Same as with other oral progestins
3.75 mg IM every month for 6 months
Decrease in bone density, estrogen deficiency
371, brand 318, generic
3.6 mg SC (in upper abdominal wall) every 28 days
400 mg per day: 1 spray in 1 nostril in a.m.; 1 spray in other nostril in p.m.; start treatment on day 2 to 4 of menstrual cycle
Estrogen deficiency, bone density changes, nasal irritation
IM = intramuscularly; SC = subcutaneously.
*—Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) for one month of treatment at the lowest dosage level in Red book. Montvale, N.J.: Medical Economics Data, 1999. Cost to patient will be greater, depending on prescription filling fee.
†—Cost based on prices of Lo-Ovral 28 and Ortho-Novum.
‡—Cost based on generic versions of Lo-Ovral 28 and Ortho-Novum.
§—For one month's therapy at 15 mg per day.
Surgical treatment is the preferred approach to infertile patients with advanced endometriosis.12 The benefit of surgery in these patients may be due entirely to the mechanical clearance of adhesions and obstructive lesions (Figure 2). Some of the endometrial lesions are cystic or nodular and can be excised (Figures 3,4 and 5), while some are hemorrhagic or petechial and amenable to laser obliteration (Figures 6 and 7). Until recently, surgery in infertile patients with limited disease was thought to be no better than expectant management. However, a recent randomized, controlled study involving 341 infertile women with minimal or mild endometriosis demonstrated a 13 percent absolute increase in the probability of pregnancy in a 36-week period.23 Infertile patients with documented endometriosis can benefit from the same reproductive techniques (e.g., superovulation, in vitro fertilization) that are used in other infertile patients.24,25
The usefulness of conservative surgery for pain relief is unclear, but it appears that immediate postoperative efficacy is at least as high as with medical treatment, and long-term outcomes may be considerably higher.26 Laparoscopy is much more expensive than medical treatment, however, causing some physicians to argue that overall costs can be reduced by aggressive use of empiric treatments before surgery is considered.16 Table 3 summarizes the advantages and disadvantages of medical and surgical treatments.
TABLE 3 Surgical vs. Medical Treatment of Endometriosis
Surgical vs. Medical Treatment of Endometriosis
Beneficial for infertility
Possibly better long-term results
Option for definitive treatment
Decreased initial cost
Adverse effects common
Unlikely to improve fertility
Effective for pain relief
Definitive surgery, which includes hysterectomy and oophorectomy, is reserved for use in women with intractable pain who no longer desire pregnancy.27 In less severe cases, one ovary may be retained to preserve ovarian function, although improvement will be less definitive. Women who have undergone oophorectomy should be treated with estrogen replacement, even at the risk of some recurrence.27
In practical terms, when the diagnosis of endometriosis is made at laparoscopy, surgical ablation of lesions is frequently performed. Thus, because laparoscopic diagnosis is usually recommended before instituting treatment, most women with endometriosis undergo surgical therapy initially. It is generally agreed that an expert surgeon who is extensively trained in ablation procedures will have the best outcomes9 (Figure 8).
Perhaps the strongest reason for beginning with surgical treatment is the apparently lower recurrence rate compared with medical treatment.27 Early studies of conservative surgical therapy showed a laparoscopically defined cumulative five-year recurrence rate of about 19 percent.28,29 The long-term benefit of surgical intervention for pain is enhanced by definitive surgery, including bilateral oophorectomy, with a 10 percent cumulative recurrence after 10 years.27 This rate is considerably lower than those following medical therapy. In one study of recurrence after medical treatment, cumulative five-year rates of recurrence were 53.4 percent.30 Unfortunately, patients whose presenting complaint was pain and those seeking treatment for infertility were grouped together in the analysis. Other studies show similar recurrence rates, regardless of the medical therapy used.26 At least one study noted higher recurrence rates in patients with more advanced stages of disease.30
Combining or repeating treatments may result in better long-term outcomes, but studies of combined treatments are inconclusive because of lack of randomization, small sample size or insufficient follow-up time. One randomized, double-blind study31 showed additional pain relief and objective improvement with immediate postoperative treatment with danazol or medroxyprogesterone, but the study ended with a second laparoscopy after six months, too soon to identify longer-term benefits. In a more recent investigation, it was found that the best and only statistically significant long-term outcomes were achieved with surgery followed by danazol treatment; however, the study was limited by a small sample size.32 Although few studies have been conducted to evaluate retreatment with danazol or GnRH analogs, repeated administrations of these drugs are theoretically an option and are probably safe at appropriate intervals.33
Figure 9 depicts an algorithmic approach to management of endometriosis based on whether pain or infertility is the presenting complaint.
1. Dmowski WP, Lesniewicz R, Rana N, Pepping P, Noursalehi M. Changing trends in the diagnosis of endometriosis: a comparative study of women with pelvic endometriosis presenting with chronic pelvic pain or infertility. Fertil Steril. 1997;67:238–43.
2. Moen MH, Magnus P. The familial risk of endometriosis. Acta Obstet Gynecol Scand. 1993;72:560–4.
3. Eskenazi B, Warner M. Epidemiology of endometriosis. Obstet Gynecol Clin North Am. 1997;24:235–58.
4. Lu PY, Ory SJ. Endometriosis: current management. Mayo Clin Proc. 1995;70:453–63.
5. Thomas EJ. Endometriosis, 1995—confusion or sense? Int J Gynecol Obstet. 1995;48:149–55.
6. Brosens IA. Endometriosis—a disease because it is characterized by bleeding. Am J Obstet Gynecol. 1997;176:263–7.
7. Gleicher N. Immune dysfunction—a potential target for treatment in endometriosis. Br J Obstet Gynaecol. 1993;102(12 suppl):4–7.
8. Martinez-Roman S, Balasch J, Creus M, Fabregues F, Carmona F, Vilella R, et al. Immunological factors in endometriosis-associated reproductive failure: studies in fertile and infertile women with and without endometriosis. Hum Reprod. 1997;12:1794–9.
9. American College of Obstetricians and Gynecologists. Endometriosis. ACOG technical bulletin no. 184. Washington, D.C.: ACOG, 1993.
10. Medl M, Ogris E, Peters-Engl C, Mierau M, Buxbam P, Leodolter S. Serum levels of the tumour-associated trypsin inhibitor in patients with endometriosis. Br J Obstet Gynaecol. 1997;104:78–81.
11. Brinton DA, Quatrociocchi-Longe TM, Kiechle FL. Endometriosis: identification by carbonic anhydrase autoantibodies and clinical features. Ann Clin Lab Sci. 1996;26:409–20.
12. Olive D, Schwartz LB. Endometriosis. N Engl J Med. 1993;328:1759–69.
13. Ripps BA, Martin DC. Correlation of focal pelvic tenderness with implant dimension and stage of endometriosis. J Reprod Med. 1992;37:620–4.
14. Stovall DW, Bowser LM, Archer DF, Guzick DS. Endometriosis-associated pelvic pain: evidence for an association between the stage of disease and a history of chronic pelvic pain. Fertil Steril. 1997;68:13–8 [Published erratum in Fertil Steril. 1998;69: 979]
15. Revised American Fertility Society classification of endometriosis. Fertil Steril. 1985;43:351–2.
16. Heinrichs WL, Henzl MR. Human issues and medical economics of endometriosis. J Reprod Med. 1998;43(3 suppl):299–308.
17. Hull ME, Moghissi KS, Magyar DF, Hayes MF. Comparison of different treatment modalities of endometriosis in infertile women. Fertil Steril. 1987;47:40–4.
18. Telimaa S, Puolakka J, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol. 1987;1:13–23.
19. Bromham DR, Booker MW, Rose GL, Wardle PG, Newton JR. Updating the clinical experience in endometriosis—the European perspective. Br J Obstet Gynaecol. 1995;102(12 suppl):12–6.
20. Kiesel L, Schweppe KW, Sillem M, Siebzehnrubl E. Should add-back therapy for endometriosis be deferred for optimal results? Br J Obstet Gynaecol. 1996;103(14 suppl):15–7.
21. Moghissi KS. Add-back therapy in the treatment of endometriosis: the North American experience. Br J Obstet Gynaecol. 1996;103(14 suppl):14.
22. Vercellini P, Cortesi I, Crisgnani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. 1997;68:393–401.
23. Marcoux S, Maheux R, Berube S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. N Engl J Med. 1997;337:217–22.
24. Tummon IS, Asher LJ, Martin JS, Tulandi T. Randomized controlled trial of superovulation and insemination for infertility associated with minimal or mild endometriosis. Fertil Steril. 1997;68:8–12.
25. Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T. Benefit of in vitro fertilization treatment for endometriosis-associated infertility. Fertil Steril. 1996;66:974–9.
26. Revelli A, Modotti M, Ansaldi C, Massobrio M. Recurrent endometriosis: a review of biological and clinical aspects. Obstet Gynecol Surv. 1995;50:747–54.
27. Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril. 1995;64:898–902.
28. Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease. Fertil Steril. 1991;56:628–34.
29. Wheeler JM, Malinak LR. Recurrent endometriosis. Contrib Gynecol Obstet. 1987;16:13–21.
30. Waller KG, Shaw RW. Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril. 1993;59:511–5.
31. Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery. Gynecol Endocrinol. 1987;1:363–71.
32. Mahmood TA, Templeton A. The impact of treatment on the natural history of endometriosis. Hum Reprod. 1990;5:965–70.
33. Hornstein MD, Yuzpe AA, Burry K, Buttram VC Jr, Heinrichs LR, Soderstrom RM, et al. Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density. Fertil Steril. 1997;67:1013–8.
Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions